ENLV Nov 2024 2.500 call
| Previous close | 1.1500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.2500 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireEnlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,42
- GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance an
Simply Wall St.We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
